AVBP Q1 2024 Earnings — ArriVent BioPharma, Inc. Common Stock Revenue & Financial Results | Market Cap Arena

AVBPArriVent BioPharma, Inc. Common Stock

$1B

Q1 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$21M

Net Income

-$17M

EPS (Diluted)

$-0.52

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$19M

Free Cash Flow

-$19M

Stock-Based Comp.

$625,000

Balance Sheet

Total Assets

$328M

Total Liabilities

$10M

Stockholders' Equity

$318M

Cash & Equivalents

$317M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$21M	-$12M	-69.8%
Net Income	-$17M	-$12M	-43.1%